Transgenomic has appointed David Pauluzzi to its board of directors. Pauluzzi is a consultant at Water Street Healthcare Partners, a Chicago-based private equity firm specializing in the healthcare sector.
Pauluzzi previously served as executive director and vice president of Quest Diagnostics, where he directed operations, marketing, and sales for the company’s esoteric anatomic pathology business and managed the sales and marketing organization for its hospital division. He also served as VP of sales and marketing and COO for US Labs, a national anatomic pathology reference laboratory.
He has also held sales and marketing positions at Ventana Medical Systems and Abbott Laboratories.
Rosetta Genomics last week announced the establishment of its medical advisory board.
Moshe Hod, a professor of obstetrics and gynecology at the Helen Schneider Hospital for Women at the Rabin Medical Center, Tel-Aviv University, will serve as chairman of the board.
Also joining the board are Harvey Pass, professor of cardiothoracic surgery and surgery at New York University School of Medicine; David Sidransky, a professor of oncology, otolaryngology, cellular and molecular medicine, urology, genetics, and pathology at Johns Hopkins University; Isaac Yaniv, chairman of the pediatric hematology oncology division at the Schneider Children's Medical Center; Jack Baniel, professor of urology at the Rabin Medical Center; Raphael Catane, a professor of oncology at the Chaim Sheba Medical Center, Tel Hashomer; and Maya Gottfried, a lung oncology researcher at the Meir Medical Center.
Wyeth last week announced that its board of directors has elected Timothy Cost, formerly executive vice president of corporate affairs at Aramark, to the position of senior vice president of corporate affairs. Cost will replace Marily Rhudy who plans to retire.
Cepheid announced this week that Andrew Miller will be the company’s new senior vice president and chief financial officer starting April 14. Miller comes from AutoDesk, where he was vice president and chief accounting officer in charge of worldwide accounting, compliance, SEC reporting, and Sarbanes-Oxley 404 activities. He will report to Cepheid CEO John Bishop and replace John Sluis who retired from Cepheid December 31.